sch 58261 has been researched along with regadenoson in 2 studies
| Studies (sch 58261) | Trials (sch 58261) | Recent Studies (post-2010) (sch 58261) | Studies (regadenoson) | Trials (regadenoson) | Recent Studies (post-2010) (regadenoson) |
|---|---|---|---|---|---|
| 46 | 0 | 14 | 321 | 53 | 264 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, ZG; Jacobson, KA | 1 |
| de Lera Ruiz, M; Lim, YH; Zheng, J | 1 |
2 review(s) available for sch 58261 and regadenoson
| Article | Year |
|---|---|
Adenosine receptors as therapeutic targets.
Topics: Animals; Disease; Drug Therapy; Humans; Ligands; Molecular Structure; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Signal Transduction; Structure-Activity Relationship | 2006 |
Adenosine A2A receptor as a drug discovery target.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction | 2014 |